ASCO 2024 | The future of AdAPT-001 in patients with solid tumors refractory to checkpoint inhibitors
Lucy Kennedy
• 2 Jun 2024
Lucy Kennedy, MD, Cleveland Clinic, Cleveland, OH, discusses the potential of incorporating AdAPT-001, an novel oncolytic adenovirus combined with a TGF-β trap, into the current treatment landscape for patients with solid tumors who have progressed on checkpoint inhibitors. As durable responses were recorded in a Phase I/II trial (NCT04673942), the investigatory treatment is a promising option in this field. A Phase II trial is being planned, with a separate sarcoma cohort. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
